Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2011 May 27;286(28):24957–24965. doi: 10.1074/jbc.M111.221416

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2011 by The American Society for Biochemistry and Molecular Biology, Inc.

PMC Copyright notice

FIGURE 5. — SAP97 is involved in D₄ potentiation of AMPAR transmission in PFC pyramidal neurons at the low activity state. A, immunocytochemical staining of SAP97 or PSD95 (red) in cultured (14–16 or 21–24 days in vitro) PFC neurons transfected with SAP97 siRNA or a scrambled siRNA (co-transfected with GFP). Arrowheads point to GFP⁺ neurons. B, cumulative plots of the distribution of mEPSC amplitudes before (control) and after PD168077 application in scrambled siRNA-transfected or SAP97 siRNA-transfected PFC pyramidal neurons pretreated with TTX (0.5 μm, 2 h). Insets, representative mEPSC traces. Scale bars, 20 pA, 1 s. C, bar graphs (mean ± S.E. (error bars)) showing the percentage increase of mEPSC amplitude and frequency by PD168077 in TTX-pretreated PFC pyramidal neurons transfected with a scrambled siRNA or SAP97 siRNA. *, p < 0.001, ANOVA. D and E, plot of AMPAR-EPSC showing the effect of PD168077 in PFC pyramidal neurons (TTX-pretreated) injected with SSG peptide (50 μm) versus a scrambled control peptide (D), or anti-SAP97 (10 μg/ml) versus the heat-inactivated antibody (E). F, bar graphs (mean ± S.E.) showing the percentage change of AMPAR-EPSC by PD168077 in the presence of various agents. *, p < 0.001, ANOVA.